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Bioinformatics
Protein synthesisThe stress-responsive, tumor suppressor N-myc downstream-regulated gene 2 (Ndrg2) is highly expressed in
striated muscle. In response to anabolic and catabolic signals, Ndrg2 is suppressed and induced, respectively, in
mouse C2C12myotubes. However, little is known about themechanisms regulatingNdrg2 expression inmuscle,
as well as the biological role for Ndrg2 in differentiated myotubes. Here, we show that Ndrg2 is a target of a per-
oxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) and estrogen-related receptor alpha
(ERRα) transcriptional program and is induced in response to endurance exercise, a physiological stress
known also to increase PGC-1α/ERRα activity. Analyses of global gene and protein expression proﬁles in
C2C12 myotubes with reduced levels of NDRG2, suggest that NDRG2 affects muscle growth, contractile proper-
ties, MAPK signaling, ion and vesicle transport and oxidative phosphorylation. Indeed, suppression of NDRG2 in
myotubes increased protein synthesis and the expression of fast glycolytic myosin heavy chain isoforms, while
reducing the expression of embryonic myosin Myh3, other contractile-associated genes and the MAPK p90
RSK1. Conversely, enhanced expression of NDRG2 reduced protein synthesis, and furthermore, partially blocked
the increased protein synthesis rates elicited by a constitutively active form of ERRα. In contrast, suppressing or in-
creasing levels of NDRG2did not affectmRNAexpression of genes involved inmitochondrial biogenesis that are reg-
ulated by PGC-1α or ERRα. This study shows that in C2C12myotubesNdrg2 is a novel PGC-1α/ERRα transcriptional
target, which inﬂuences protein turnover and the regulation of genes involved in muscle contraction and function.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
N-myc downstream-regulated gene 2 (Ndrg2) and its family mem-
bers are stress- and differentiation-responsive genes that regulate the
proliferation of many cell types (reviewed in [1]). NDRG2 is highly
expressed in brain, liver, heart and skeletal muscle [2–4]. In poorly
differentiated, highly proliferative cells such as cancer cells, NDRG2
expression is typically very low and is thought to function as a tumor
suppressor, slowing cell growth [5,6]. NDRG2 has been suggested to
regulate ion transport and homeostasis [7], affect liver ﬁbrosis [8], and
protect against lipotoxicity in pancreatic beta cells [9]. We also showed
that knockdown of NDRG2 attenuates myoblast proliferation and com-
promises differentiation [10] although its role in differentiatedmyotubes
is unknown.
Ndrg2 appears highly phosphorylated in skeletal muscle where it is
one of 127 proteins identiﬁed in a phosphoproteome of human skeletal
muscle [11]. Other studies have shown NDRG2 as a substrate of AGC
type kinases including thymoma viral proto-oncogene 1, serum- andndNutrition Research (C-PAN),
ersity, 221 Burwood Highway,
+61 392446017.
letta).
ights reserved.glucocorticoid-induced kinase 1 and protein kinase C theta in skeletal
muscle cells [4,12] but the functional outcomes following NDRG2 phos-
phorylation were not investigated. Recently, we determined that Ndrg2
gene and protein expression increases during the differentiation of
mouse C2C12 and humanmuscle cells. Exposure to anabolic stress con-
ditions such as resistance exercise training, insulin, insulin-like growth
factor 1 and testosterone all decrease Ndrg2 gene expression in muscle.
In contrast, catabolic stress conditions such as dexamethasone in-
crease Ndrg2 mRNA levels [10]. Together, these observations suggest
further roles for NDRG2 in skeletal muscle structure, function and pro-
tein turnover.
Despite the high expression of NDRG2 in muscle, the transcriptional
regulators of Ndrg2 gene expression and its biological function in
myotubes have not been well characterized. Peroxisome proliferator-
activated receptor gamma, coactivator -1 alpha (PGC-1α) and estrogen
related receptor alpha (Esrra) are two genes up-regulated during
myogenesis [13,14] and following endurance exercise [15,16]. Similarly
to Ndrg2, PGC-1α mRNA is suppressed by insulin [17] and induced by
dexamethasone [18] in C2C12 myotubes. The PGC-1α/ERRα transcrip-
tional program regulates genes involved in numerous skeletal muscle
functions (reviewed in [19]) including oxidative metabolism [20–22],
mitochondrial biogenesis [23] and fusion [24], actin-binding [16], and
the expression of slow, oxidative ﬁber phenotypes [25] via hypoxia-
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Ndrg2 and PGC-1α/ERRα in muscle suggest a potential regulatory rela-
tionship that has not yet been explored.
In this study, we provide insights into the transcriptional regulation
of Ndrg2 by PGC-1α/ERRα in C2C12 myotubes. Furthermore, following
knockdown of Ndrg2 in C2C12 myotubes, we use global gene and
protein proﬁling combined with in vitro functional assays to identify
potential biological role(s) of NDRG2.
2. Materials and methods
2.1. Cell culture
Mouse C2C12 myoblasts (ATCC, Manassass, VA, USA) were cultured
in 5% CO2 at 37 °C in growthmedium containing 25 mMglucoseDMEM
with 2 mM glutamine and 10% fetal bovine serum (Life Technologies,
Mulgrave, VIC, AUS). When the cells reached conﬂuence, the medium
was changed to differentiation medium consisting of DMEM with 2%
horse serum to enhance myoblast differentiation over 7 days and re-
placed every 48 h.
2.2. Adenoviral infections
Infection of C2C12 myotubes with adenoviruses expressing siERRα,
human PGC-1α, VP16-ERRα and appropriate controls (siSUPER (siCON),
green ﬂuorescent protein (GFP), and VP16 alone, respectively) was as
described previously [16]. VP16-ERRα is a chimera protein in which the
VP16 activation domain is fused to the N-terminus of ERRα giving ERRα
constitutive activity [27]. Myotubes were infected using an MOI of 100
except for VP16-ERRα and VP16 control where an MOI of 50 was used.
Cells were harvested 72 h post infection on day 7 of differentiation
and processed for extraction of DNA, RNA, protein, and protein synthe-
sis and degradation analyses.
2.3. siRNA transfections and retroviral infections
Suppression ofNdrg2 in C2C12myotubeswas achieved using 100 nM
of Stealth RNAi™ siRNA (Life Technologies) with a target sequence of 5′
GAUGCCGUGGUGGAAUGUAACUCAA. The Stealth RNAi™ Negative con-
trol Med GC siRNA (Life Technologies) was used as the control siRNA.
The siRNA duplexes were transfected on day 4 of differentiation using
Lipofectamine 2000 (Life Technologies) as recommended by the manu-
facturer. Cells were harvested 72 h later.
Wild-type mouse Ndrg2 cDNA was generated using primers:
Forward: 5′ AGTGAGATCTACCATGGCAGAACTTCAGGAGGT, and Reverse:
5′GTTCGTCGACTCAACAGGAGACTTCCATGG, and cloned into SalI and
BglII sites of the pMSCV-IRES-hygromycin (pMIH) retroviral vector [28],
a kind gift from Prof D. Huang, Walter and Eliza Hall Institute of Medical
Research. Empty pMIH vector and pMIH-Ndrg2 plasmidswere transient-
ly transfected into Platinum E packaging cells [29] using Lipofectamine
2000 (Invitrogen) in the presence of OptiMem (Invitrogen) at a 1:3.3
DNA: transfection reagent ratio as recommended by the manufacturer.
Virus production and infection of C2C12 myoblasts were performed as
described previously [10]. The following day, 800 μg ml−1 of hygromycin
was added and cells were selected for 30–36 h prior to re-seeding at
6 × 104 ml−1 and differentiation.
2.4. RNA extraction, reverse transcription and real time PCR
Total RNA from C2C12 cell lysates was extracted using PureLink®
RNAMini Kit (Ambion Inc, Austin, TX, USA) and treated with DNAse I
as outlined by the manufacturer. Samples were quantitated using
the Nanodrop 1000 spectrophotometer (ThermoFisher Scientiﬁc,
Scoresby, VIC, AUS). One microgram of RNA was used to perform
ﬁrst-strand cDNA synthesis using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA)according the manufacturer's guidelines. Real time PCR analyses
were performed on the MX 3000 PCR system (Stratagene, La Jolla,
CA, USA) with Power SYBR Green Master Mix (Applied Biosystems).
The PCR conditions were: 95 °C for 10 min (1 cycle), 95 °C for 30 s
and 60 °C for 60 s (40 cycles). Relative gene expression was calculat-
ed at 2−Δct and normalized to the housekeeping gene 36B4 [30] to
compensate for variations in input cDNA. The PCR primers used in
this study are listed in Suppl. Table 1.
2.5. Protein extraction and western blotting
Proteins were lysed in a 1× modiﬁed RIPA (Merck Millipore, North
Ryde, NSW, AUS) containing 1:1000 protease inhibitor cocktail (Sigma-
Aldrich) and 1:100 Halt phosphatase inhibitor cocktail (ThermoFisher
Scientiﬁc) and left on ice for 30 min prior to centrifugation to re-
move insoluble material. Twenty-ﬁve micrograms of protein lysates
were electrophoresed on a pre-cast NuPAGE Novex 4–12% gradient
Bis-Tris gel (Life Technologies) or 8% SDS-PAGE gel and transferred
to Immobilon®-FL polyvinylidene diﬂuoride membrane (Merck
Millipore, Kilsyth, VIC, AUS). Membranes were blocked in 5% bovine
serum albumin (BSA)/phosphate buffered saline (PBS) for 1 h prior to
overnight 4 °C incubation in the primary antibodies diluted in 5% BSA/
PBS. Rabbit polyclonal anti-NDRG2 (HPA002896; 1:5000) and anti-
STARS (1:1000) antibodies were obtained from Prestige Antibodies
(Sigma-Aldrich) and developed within our group [16], respectively.
The ERRα rabbit monoclonal antibody was from Epitomics/Abcam
(cat. 2131; Sapphire Biosciences, Waterloo, NSW, AUS) and used at
1:2000 overnight in PBS only after blocking. The PGC-1α rabbit poly-
clonal antibodies (cat. 516557) were obtained from Merck Millipore
and used at 1:1000. Mouse monoclonal anti-Myh3 antibody (F1.652;
1:400) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) and the remaining antibodies (listed in Suppl. Table 2) were
from Cell Signaling (Beverly, MA, USA) and used at 1:1000. Detection
of proteins was performed using goat anti-rabbit AlexaFluor®680 or
rabbit anti-mouse AlexaFluor®800 IgG antibodies (Life Technologies)
diluted 1:5000 in 50% Odyssey blocking buffer (LI-COR Biosciences,
Lincoln, NE, USA) and 0.01% SDS in PBS on an infrared imaging system
(LI-COR Biosciences). Protein expression was normalized against HSP90
protein levels using the LI-COR software.
2.6. Chromatin immunoprecipitation (ChIP)
ChIP experiments using C2C12 myotubes infected with adenovirus
were performed as described previously [16]. Genomic DNA present in
the immunopuriﬁed complex was quantiﬁed by real time PCR using
mouse Ndrg2 primers: Forward: 5′ GGTCCTACCCAAGTGCCACTATT and
Reverse: 5′ AGGGGAGAGATGAAGGCTTGAA, which ampliﬁes a region
containing an ERRα response element (ERRE) in the ﬁrst intron of
Ndrg2 (See Suppl. Fig. 1). Positive and negative control real time PCRs
using primers speciﬁc to the characterized ERRE-containing region of
the Esrra gene (positive control) and to a region containing no ERRE
(negative control) were also performed as described previously [24]
but are not shown in this study. Data were normalized to total genomic
DNA input and then expressed as a fold-change to the PCR values from
background control anti-GFP immunoprecipitated samples.
2.7. Endurance exercise study
The biopsy samples used to analyse NDRG2 gene expression were
obtained from a previously performed endurance exercise study [16].
The exercise parameters, biopsy procedures, RNA extraction and cDNA
synthesis are described in detail in the study [16]. The study was ap-
proved by the Deakin University Human Research Ethics Committee in
accordance with the Declaration of Helsinki (2000). All participants
gave their informed consent and agreed to muscle biopsies and physio-
logical testing.
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The DNAmicroarray, data transformation and ANOVA analyseswere
performed by the Australian Genomic Research Facility (Parkville, VIC,
Australia). The quality and quantity of the RNA extracted from siRNA
transfectedmouse C2C12myotubes (a total of 3 samples per treatment)
were determined initially with the Agilent Bioanalyzer and RNA 600
Nano Assay kit (Agilent Technologies, Paolo Alto, CA). A total of 500 ng
of RNA was labeled using the Ambion Total Prep RNA ampliﬁcation kit
(Ambion). Labeled cRNA (0.05 μg/μl) was then combined with the
GEX-HYB Hybridization Buffer in a 30 μl ﬁnal volume and hybridized
to the Illumina Mouse-6v2 Expression Beadchip (Illumina Inc., San
Diego CA, USA) overnight at 58 °C for 16 h with a rocking platform.
The chips were washed as outlined in the Illumina manual, coupled
with Cy3, and scanned in the Illumina iScan Reader using GenomeStudio
software (Illumina Inc.). Raw signal intensity values were subjected to
variance stabilization transformation including background correction,
log2 transformation and variance stabilization using the lumiR package
of R Bioconductor (www.Bioconductor.org) [31,32]. ANOVA analysis of
normalized Illumina probe intensities values was performed in Partek®
Genomic SuiteTM software, version 6.6 (Partek Inc., St. Louis, MO, USA).
Pairwise comparison of sample groups was performed by ANOVA
method. Differentially expressed genes were selected by difference
in expression level over 25% (fold-change N±1.25) in compared
groups, and “nominal” ANOVA p-value b 0.05. Gene-set enrichment
analyses (GSEA) entailing gene ontology and KEGG (Kyoto Encyclope-
dia of Genes and Genomes) pathway mapping were performed on the
list of differentially expressed Illumina probes (representing genes)
using Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 (http://david.abcc.ncifcrf.gov) [33,34].
2.9. Isobaric Tags for Relative and Absolute Quantiﬁcation
Sample preparation and Isobaric Tags for Relative and Absolute
Quantiﬁcation (iTRAQ) labeling and analyses were performed as essen-
tially described previously [35] by Proteomic International (Nedlands,
WA, AUS). Brieﬂy, protein samples from siRNA transfected mouse
C2C12 myotubes were precipitated individually with acetone and
resuspended in 0.5 M triethylammonium bicarbonate, pH 8.5, prior to
being reduced, alkylated and trypsin-digested according to the iTRAQ
protocol (Applied Biosystems). Two independent experiments consisting
of peptides extracted from siRNA control (siCON)- or siNdrg2-treated
myotubes were labeled with iTRAQ reagents 114 and 116 (siCON
samples) and 115 and 117 (siNdrg2 samples). Labeled peptides
were then combined, desalted on a Strata-X 33 μm polymeric re-
versed phase column (Phenomenex, Torrance, CA) and dissolved in
10% acetonitrile with 10 mM KH2PO4, pH 3.0, prior to separation by
strong cation exchange liquid chromatography on a PolySulfoethyl
column (4.6 × 100 mm, 5 μm, 300 Å) using an Agilent 1100 HPLC
system (Agilent Technologies). A 0–400 mM KCl gradient was used
to elute fractions, which were desalted again before separation on a
C18 PepMap100, 3 mm column (LC Packings-Dionex, Sunnyvale, CA)
using an Ultimate 3000 nano HPLC system (Dionex). Peptide fractions
were resolved on a 10–40% acetonitrile/0.1% triﬂuoroacetic acid gradient,
spotted onto an AnchorChip MALDI plate using a ProBot robotic spotter
(Dionex), and analysed on a 5800 MALDI TOF/TOD Analyser (AB Sciex,
Foster City, CA). Peptide samples were identiﬁed and quantitated using
ProteinPilot 4.0.8085 software (AB Sciex), and false discovery rate was
also estimated using reversed sequences. Sequences were searched
against the Swissprot database (taxonomy = Mus musculus). For each
protein ratio (114 relative to 115 (siCON (C1) vs siNdrg2 (T1); experi-
ment #1) or 116 relative to 117 (siCON (C2) vs siNdrg2 (T2); experiment
#2)), a p-value of b0.05 was considered signiﬁcant. UniProt enrichment
terms and KEGG pathway mapping analyses were performed using
DAVID v6.7 (http://david.abcc.ncifcrf.gov/) on the list of differentially
expressed proteins represented by their UniProt nomenclature.2.10. Protein turnover
Protein synthesis and degradation experiments were performed
as described [36]. To measure protein synthesis rates, myotubes
were incubated with L-[3,5-3H]tyrosine (42.6 ci/mmol, PerkinElmer
Life Sciences, Glen Waverley, VIC, AUS) and 2 mM unlabeled (cold)
L-tyrosine in differentiation medium for 24 h in the presence or
absence of 10 nM insulin (Humulin, Eli Lily, Indianapolis, IN, USA)
or 1 μM dexamethasone (Sigma-Aldrich). Cells were then washed
with cold PBS and proteins precipitated with 10% trichloroacetic
acid (TCA; 10% w/v ﬁnal concentration) prior to pelleting the pro-
teins by centrifugation (10,000 ×g). The pellet was solubilized with
0.1 N NaOH/0.1% SDS and the amount of radioactivity measured by
liquid scintillation counting. Protein degradation rates were measured
by labeling the myotubes with L-[3,5-3H]tyrosine (42.6 ci/mmol) in dif-
ferentiation medium for 24 h. The cells were washed in serum-free
DMEM and placed in chase medium (DMEM/2% horse serum plus
2 mM cold L-tyrosine) for 2 h to limit reincorporation of the [3H]tyro-
sine. Cells were washed again and incubated for a further 24 h in
serum-free DMEMwith or without 10 nM insulin or 1 μM dexametha-
sone. The medium from each sample was removed and proteins were
precipitated with 10% TCA. Radioactivity in the media supernatants
(= soluble radioactivity) was measured using liquid scintillation
counting. The TCA precipitated medium proteins were solubilized in
0.5 NNaOH/0.1% SDS and radioactivitymeasured (= insoluble radioac-
tivity). Finally, the remaining cells were solubilized in 0.5 N NaOH/0.1%
SDS and proteins precipitated with 10% TCA overnight at 4 °C prior to
measuring the radioactivity (=myotube radioactivity). Degradation
was deﬁned as the soluble radioactivity/(soluble radioactivity +
insoluble radioactivity + myotube radioactivity) × 100. The ﬁnal
amounts for the protein synthesis and degradation rates are expressed
as a percentage change to the control samples.
2.11. Statistics
Data are presented as mean ± S.E.M. Statistical signiﬁcance was
assessed using unpaired Student's t-test, one- or two-way ANOVA
with Bonferroni post hoc comparisons using GraphPad Prism 4 statisti-
cal software (GraphPad Software Inc., La Jolla, CA, USA). A p-value of
b0.05 was considered signiﬁcantly different.
3. Results
3.1. PGC-1α/ERRα and endurance exercise induces NDRG2 expression
Endogenous PGC-1a and ESRRa gene expression are increased 3 h
following an acute bout of endurance cycling exercise [16]. We mea-
sured NDRG2mRNA in the biopsy samples fromWallace, 2011 and ob-
served a 2.5-fold (P b 0.001) and 1.5-fold (P b 0.05) increase in NDRG2
gene expression at 3 and 24 h post exercise, respectively (Fig. 1A). As
this observation paralleled that of PGC-1a and ESRRamRNA it was of in-
terest to see if Ndrg2 was a potential transcriptional target of PGC-1α/
ERRα signaling. Bioinformatic analysis of the genomic sequence from
themouseNdrg2 promoter region indicated six putative ERRα response
elements (ERRE) related to the 9 bp ERRE consensus site 5′-N(C/G)
AAGGTCA-3′ [37]. Among the putative ERREs, two are an exact match
to a consensus ERRE, 5′-ACAAGGTCA and 5′-TGAAGGTCA, which
appear well conserved across several mammalian species (Fig. 1B),
and are located 1252 and 569 bp upstream of the translation start site,
respectively (Suppl. Fig. 1). Infection of mouse C2C12 myotubes with
an adenovirus-expressing human PGC-1α resulted in a 5-fold increase
in mouse Ndrg2mRNA (P b 0.05) and a concurrent induction of NDRG2
protein (Fig. 1C). An increase in endogenous ERRα protein levels was
noted as a result of PGC-1α overexpression, as shown previously
[21,38]. The induction inNdrg2 expressionby PGC-1αwas strongly atten-
uated when endogenous ERRα expression was suppressed by shRNA
A B
C D
E
Fig. 1. Endurance exercise and PGC-1α/ERRα regulation of Ndrg2 expression in skeletal muscle (A) Effect of acute endurance exercise on human NDRG2 gene expression. Pre, before ex-
ercise; 3 h, 3 h post-exercise; 24 h, 24 h post-exercise. ***P b 0.001 to pre and *P b 0.05 to pre; n = 9per group. (B) Two conserved ERREs (5′-N(C/G)AAGGTCA-3′; boxed region) present
in intron 1 of themouse, rat and human Ndrg2 genes. Nucleotide conservation is highlighted in bold. (C)Ndrg2mRNA (upper panel) and protein (lower panel) levels in C2C12myotubes
following the overexpression of green ﬂuorescent protein (GFP; control protein) or PGC-1α in the presence or absence of ERRα suppression (siERRa) or its control siCON following ade-
noviral infection. Statistical signiﬁcance in one-way ANOVAwith Bonferroni post-hoc analyses: *P b 0.05 to GFP siCON; n = 3 samples per group. (D) Ndrg2 gene and protein expression
after the overexpression of VP16-control (VP16) or constitutively active ERRα (VP16-ERRa). The protein expression levels for PGC-1α, ERRα and loading control heatshock protein 90
(HSP90) are also shown. Statistical signiﬁcance in unpaired Student's t-test: **P b 0.01 to VP16; n = 3 per group. (E) Binding of FLAG-tagged PGC-1α (FLAG-PGC-1a) and endogenous
ERRα at the ERRE site in the mouse Ndrg2 gene (5′-ACAAGGTCA; Panel B and Suppl. Fig. 1), determined by chromatin immunoprecipitation (ChIP) studies. ChIPs were performed with
anti-GFP, anti-FLAG or anti-ERRα antibodies, and chromatin from cells expressing either control (LacZ) or FLAG-PGC-1α, in the presence of control (siCON) or siRNA speciﬁc for ERRα
(siERRa) following adenoviral infection. Ndrg2-ERRE enrichment in the immunoprecipitated chromatin was quantiﬁed by real time PCR, normalized to input signal and expressed as a
fold-change to the anti-GFP background control values as indicated on the y-axis. On the x-axis, the ChIP antibodies are indicated. Speciﬁc antibody (anti-FLAG or anti-ERRa) versus
non-speciﬁc antibody (anti-GFP): ***P b 0.001 to anti-GFP controls; and FLAG-PGC-1a or siERRa effect: ^P b 0.01 to respective LacZ/siCON control groups. Data are the mean ± SEM of
two independent experiments (n = 5 total).
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constitutively active formof ERRα, resulted in a 6-fold increase inNdrg2
mRNA (P b 0.01) and increased NDRG2 protein expression (Fig. 1D). To
test if PGC-1α, together with ERRα, acts directly at the mouse Ndrg2
gene to induce its expression, chromatin immunoprecipitation (ChIP)
experiments in mouse C2C12 myotubes were performed. PGC-1α
binding to the region that includes the ERRE, 5′-ACAAGGTCA, wasdetected speciﬁcally in cells that express FLAG-PGC-1α. This bind-
ing was dependent on the presence of endogenous ERRα as it
was signiﬁcantly diminished in cells expressing siERRα (P b 0.001;
Fig. 1E). Endogenous ERRα was also detected binding at the same
ERRE-containing region, and as expected, ERRα occupancy was in-
creased in cells expressing FLAG-PGC-1α and diminished by siERRα
(P b 0.01; Fig. 1E).
Table 1
KEGG pathway terms determined from DNA microarray gene expression proﬁles follow-
ing Ndrg2 suppression in C2C12 myotubes.
KEGG pathway term Count % p-value
Oxidative phosphorylation 10 5 2.41E−05
Parkinson's disease 9 4 1.90E−04
Alzheimer's disease 10 5 3.26E−04
Huntington's disease 9 4 0.002
Cardiac muscle contraction 6 3 0.002
MAPK signaling pathway 9 4 0.015
Ribosome 5 2 0.023
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To gain insights into themolecules and signaling pathways regulated
by Ndrg2 in muscle cells, endogenous Ndrg2 expression levels were
suppressed in differentiated mouse C2C12 myotubes using siRNA. DNA
microarray analyses identiﬁed 222 genes that were signiﬁcantly altered
by a minimum of 1.25 fold; 110 genes increased while 112 genes
decreased (P b 0.05; Suppl. Table 3). Gene pathway and gene-set en-
richment analyses (GSEA) using DAVID bioinformatics resources
(http://david.abcc.ncifcrf.gov) [33] were then performed on the
222 signiﬁcantly regulated genes. Gene ontology (GO) annotations
revealed 73 of the genes were clustered signiﬁcantly with a range
of biological processes including oxidation–reduction and the electron
transport chain, vesicle-mediated transport, generation of precursor
metabolites and energy, membrane endocytosis, muscle development,A
B
C
Fig. 2.GeneOntology (GO) terms of enriched clusters of geneswhose expression is altered
by suppression of NDRG2 in C2C12 myotubes: (A) Biological Process, (B) Cellular Compart-
ment, and (C)Molecular Function. Number of genes in eachGO term is indicated in brackets.
All categories represent groups of genes with a modiﬁed Fisher Exact Score p-value, EASE
score of b 0.05.and regulation of the MAPK pathway (Fig. 2A). Approximately 20% of
the 73 genes were found listed in more than one category (Suppl.
Table 3). There were 66 genes signiﬁcantly enriched with GO cellular
compartment annotations including the mitochondrial membrane
and envelope, ribosome and ribonucleoprotein complex, myoﬁbril/
sarcomere structures and actin cytoskeleton, the respiratory chain
and sarcoplasmic reticulum (Fig. 2B). Again, approximately 20% of
these genes were listed in more than one category (Suppl. Table 3).
Forty-four genes had signiﬁcant associations with GO molecular func-
tions including actin/cytoskeleton and calmodulin binding, structural
molecule and hydrogen ion transporter activities, and with peroxidase
and aldehyde dehydrogenase activities (Fig. 2C). About 5% of these
genes were found listed under more than one category (Suppl. Table 3).
KEGG pathway databases identiﬁed signiﬁcant enrichment between the
altered genes with oxidative phosphorylation (OXPHOS) and the neuro-
degenerative diseases Parkinson's, Alzheimer's and Huntington's disease,
cardiac muscle contraction, MAPK signaling and the ribosome (Table 1).
The genes clustered in OXPHOS and the neurodegenerative diseases
KEGG pathways were clearly overlapping as well as with a few in the
muscle contraction group (Suppl. Table 4). Interestingly, many of these
clustered genes tended to be regulated in one direction such as the
increased expression in the OXPHOS and ribosome groups, or reduced
expression as seen in the MAPK signaling group including the MAPK,
p90 RSK1, also known as Rps6ka1 (Suppl. Table 4).
3.3. Proteomic proﬁling of myotubes following NDRG2 suppression
Proteomics analyses of protein lysates expressing reduced levels of
NDRG2 was also performed using iTRAQ [39] to determine signiﬁcant
changes in protein expression. Two independent experiments were
performed. A total of 35 and 44 proteins were signiﬁcantly regulated
from each experiment, respectively (P b 0.05, Suppl. Table 5). Thirteen
of these proteins were common to each iTRAQ experiment and are
listed in Table 2. Of note was the down regulation of the myosin
heavy chain (Myh) 3 protein, the gene expression ofwhichwas also sig-
niﬁcantly down regulated in the microarray screen (Suppl. Table 3). InTable 2
Common proteins identiﬁed in C2C12 myotube lysates with suppressed levels of Ndrg2
from two independent iTRAQ experiments.
UniProt # Protein name Direction of
regulation
Expt#1 Expt#2
P13541 Myosin,3- Down Down
O08795 Glucosidase-2-subunit-beta Down Down
Q8BH64 EH-domain,containing-protein-2 Up Up
Q8BP47 Asparaginyl,tRNA-synthetase,-cytoplasmic Down Down
P50543 Protein-S100,A11 Up Up
P20152 Vimentin Down Down
Q9JII5 DAZ-associated-protein 1 Down Down
Q9CQ92 Mitochondrial ﬁssion 1 protein Down Down
P61982 14-3-3 protein gamma Down Up
P56135 ATP synthase subunit f, mitochondrial Up Up
Q9JJ28 Protein ﬂightless-1 homolog Up Down
Q9DCS9 NADH dehydrogenase 1 beta subunit 10 Up Up
Table 4
KEGG pathway analyses of iTRAQ protein expression proﬁles following Ndrg2 suppression.
Two independent experiments are indicated.
KEGG pathway Count % p-value
Experiment#1
Tight junction 4 11 0.007
Huntington's disease 4 11 0.016
Regulation of actin cytoskeleton 4 11 0.025
Experiment#2
Ribosome 3 7 0.038
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ment associated with myoblast and muscle regeneration [40,41], were
reduced in both iTRAQ experiments. GSEA of each protein list revealed
signiﬁcant GO annotations for each experiment and are listed in Suppl.
Table 5. GSEA also revealed overlapping enrichment of the proteins
with a number of UniProt keyword terms including actin-binding and
cytoskeleton, ATP-binding, myosin and calcium between both experi-
ments (Table 3). Subcellular localization of many proteins highlighted
the cytoplasm and mitochondrion terms as well as the endoplasmic
reticulum (Table 3). Post-translational modiﬁcation terms revealed
that more than 50% of the affected proteins were associated with
phosphorylation and/or acetylation (Table 3). KEGG pathway analyses
of the protein expression proﬁles revealed signiﬁcant enrichment of
the proteins with the tight junction, Huntington's disease, regulation
of actin and with the ribosome (Table 4).
3.4. Expression of members of the MAPK signaling pathway, contractile-
type genes and markers of mitochondrial biogenesis
We next investigated some of the differentially expressed gene and
proteins, GO terms and KEGG pathways identiﬁed from the microarray
and iTRAQ screens linked to muscle mass changes, mitochondria and
MAPK signaling. We measured the expression levels of various muscle
myosin isoforms, actin-binding and contractile-linked genes, as well as
several markers of mitochondrial biogenesis and MAPKs, following the
suppression or enhanced expression of NDRG2. Of the MAPK members
investigated, no difference in the phosphorylated or total p38 and p42/
p44 MAPKs (also known as ERK1/2) were found (Fig. 3A). However, an
approximate 60% decrease in the total and phosphorylated forms of p90
RSK1wasmeasured following suppression of NDRG2 (P b 0.05). Of note,
a 1.7-fold decrease in p90 RSK1 (Rps6ka1), gene expression was found
following DNA microarray analyses (Suppl. Tables 3 & 4), which corre-
lates with the decrease in protein expression measured. In contrast, no
difference in total or phosphorylated p90 RSK1 levelswasmeasured fol-
lowing NDRG2 overexpression.Table 3
UniProt Keyword terms determined from iTRAQ protein expression proﬁles following
Ndrg2 suppression. Two independent experiments are indicated.
UniProt term Count % p-value
Experiment#1
Acetylation 18 51 2.17E−07
Phosphoprotein 24 69 1.26E−04
Actin-binding 5 14 8.61E−04
Motor protein 4 11 0.002
Cytoplasm 14 40 0.003
Myosin 3 9 0.004
Calcium 6 17 0.012
Mitochondrion 6 17 0.016
ATP synthesis 2 6 0.021
Isomerase 3 9 0.021
Atp-binding 7 20 0.033
Endoplasmic reticulum 5 14 0.039
Cell shape 2 6 0.047
Mitochondrion inner membrane 3 9 0.047
Experiment#2
Acetylation 26 59 3.70E−12
Cytoplasm 21 48 6.46E−06
Actin-binding 6 14 2.02E−04
Mitochondrion 9 20 5.19E−04
Phosphoprotein 27 61 6.75E−04
Calcium 7 16 0.008
Cytoskeleton 6 14 0.013
Muscle 2 5 0.019
Transit peptide 5 11 0.024
Ribonucleoprotein 4 9 0.026
ATP-binding 8 18 0.033
Lyase 3 7 0.035
Nucleotide-binding 9 20 0.039A number of Z disc-associated and actin-binding genes whose gene
expressions were listed as reduced by DNA microarray analysis (Suppl.
Table 3)weremeasured. Desmin and tropomyosin 2 (Tpm2) gene expres-
sion tended to decrease butwere not signiﬁcantwhile themRNA levels of
STARS/Abra (striatedmuscle activator of Rho signaling), telethonin (Tcap)
and dysferlin-interacting protein 1 (dysﬁp1), also known as protein phos-
phatase 1, regulatory subunit 27 (Ppp1r27), were all decreased following
NDRG2 suppression (P b 0.05; Fig. 3B); however, they did not change fol-
lowing overexpression of NDRG2. Suppression of STARS at the protein
level following NDRG2 knockdown was also not conﬁrmed.
Suppression of NDRG2 levels increased the mRNA levels of myo-
sin genes associated with fast twitch, glycolytic ﬁber-types, Myh1,
Myh4 and Myh2, by nearly 150%, 80% and 70%, respectively (P b 0.05).
Embryonic Myh3 gene expression decreased by 60% (P b 0.01) and a
75% decrease in Myh3 protein expression was also observed (P b 0.001;
Fig. 3C). The suppression of Myh3 expression conﬁrms the ﬁndings
from the DNA microarray (Suppl. Table 3) and iTRAQ outcomes
(Table 4). In contrast, following overexpression of NDRG2, Myh1
and Myh4 gene expression decreased by 30% and 42%, respectively,
whileMyh7 andMyh2 did not change.Myh3 gene expression tended
to decrease but was not signiﬁcant nor any change measured at the pro-
tein level. As a comparison,we alsomeasured the effects of overexpressed
PGC-1α and constitutively active VP16-ERRα on the same myosin heavy
chain genes and found that both caused a signiﬁcant decrease in the
mRNA levels of the faster-twitch, glycolytic myosins as well as Myh3
(P b 0.05; Suppl. Fig. 2A). VP16-ERRα increased slow-twitch, oxidative
myosin, Myh7, 10-fold. Interestingly, increased levels of PGC-1α de-
creasedMyh7mRNA, whichwas perhaps unexpected given that exoge-
nously expressed PGC-1α in transgenic mice normally drives slow
twitch ﬁber expression [25] includingMyh7mRNA in rat primary mus-
cle cell cultures [42]. We were unable to ﬁnd other reports describing
the effect of overexpressed PGC-1α in C2C12 muscle cells on Myh7
gene expression to compare with.
While mitochondrial biogenesis did not appear as a GO term with
the screens performed following NDRG2 suppression, many mito-
chondrial genes and proteins were listed. As PGC-1α and ERRα are
potent inducers of mitochondrial biogenesis, we investigated some
transcription factors that are responsive to endurance exercise or
low mitochondrial content conditions including mitochondrial tran-
scription factor A (Tfam), nuclear respiratory factor 1 (Nrf1), mitofusin
(Mfn) 1 and 2 (reviewed in [19])withMfn 1 [24] andMfn2 [15] also tran-
scriptionally induced directly by PGC-1α/ERRα activity. However, nei-
ther suppressed nor enhanced levels of NDRG2 altered Tfam, Nrf1,Mfn1
and Mfn2 mRNA levels (Fig. 3D, top panel) while both PGC-1α and
VP16-ERRα induced Mfn1 and Mfn2, but not Nrf1, and overexpressed
PGC-1α also increased Tfam (P b 0.05; Suppl. Fig. 2B).
3.5. NDRG2 regulates protein synthesis and its increased expression reduces
VP16-ERRα-induced protein synthesis
Wenext investigatedwhether altering the levels of NDRG2 impacted
on protein turnover as an indicator of possible changes in muscle mass
and remodeling, and ribosomal activity as revealed from the bioinfor-
matics analyses of themicroarray and iTRAQ screens. In vitro assessment
AB
C
D
Fig. 3.MAPK protein, contractile and mitochondrial biogenesis associated gene expression following suppression and overexpression of NDRG2 in C2C12 myotubes. (A) Immu-
noblotting analyses of total and phosphorylated (P) protein expression levels of members of the MAPK signalling pathway following knockdown of NDRG2 using siRNA
(siNdrg2) compared with siRNA control (siCON) or overexpression of empty vector (vector) and NDRG2 (Ndrg2) with retroviral infection. Total and phospho-p90 RSK1
(RSK1) protein levels are shown in the right hand panels. siCON (white bars) and siNdrg2 (grey bars). (B) Actin-binding and Z-disc-associated, (C) myosin heavy chain, and
(D) mitochondrial biogenesis associated gene expression proﬁles following suppression or overexpression of NDRG2. STARS and Myh3 protein levels are shown in the right
hand panels. siCON (white bars); siNdrg2 (grey bars); empty vector (striped bars); and overexpressed NDRG2 (black bars). Tpm2, tropomyosin2; Tcap, telethonin; STARS, stri-
ated muscle activator of Rho-dependent signaling; Dysﬁp1, dysferlin-interacting protein 1; Myh, myosin heavy chain; Tfam, mitochondrial transcription factor A; Nrf1, nuclear
respiratory factor 1; Mfn; mitofusin. Statistical signiﬁcance in unpaired Student's t-test: *P b 0.5, **P b 0.01 or ***P b 0.001 to relevant control (siCON or vector); n = 3–4 per
group and blotting images are representative.
3118 V.C. Foletta et al. / Biochimica et Biophysica Acta 1833 (2013) 3112–3123
3119V.C. Foletta et al. / Biochimica et Biophysica Acta 1833 (2013) 3112–3123was undertaken during basal and stress conditions known to alter both
protein synthesis and degradation rates. As expected, insulin and dexa-
methasone treatments caused a signiﬁcant increase and decrease in pro-
tein synthesis, respectively, while the reverse occurred during protein
degradation measurements (Fig. 4A and B). Following NDRG2 suppres-
sion, basal and insulin-stimulated protein synthesis rates were found
increased by nearly 20% (P b 0.01; Fig. 4A) whereas no change was
found in the dexamethasone-treated samples. Conversely, overexpressed
NDRG2 decreased protein synthesis rates by 15–20% under basal and
insulin-treated conditions (P b 0.05) with no change found under
dexamethasone-treated conditions. In the protein degradation ex-
periments, insulin and dexamethasone decreased and increased
protein degradation, respectively (P b 0.001; Fig. 4B); however, no
changes in protein degradation rates were found following suppressionA
B
C
Fig. 4. Protein turnover analyses following suppression and overexpression of NDRG2 levels in
NDRG2 by siRNA (siNdrg2; grey bars) compared to control siRNA-transfected samples (siCON;w
(vector; striped bars). Myotubes were treated under basal, 10 nM insulin or 1 μM dexamethaso
blotting analyses following exogenous NDRG2 and adenovirus VP16-ERRα overexpression. Stat
overexpression effect: *P b 0.05 and **P b 0.01 to control groups; and treatment (insulin, dex or
siNdrg2, Ndrg2 or VP16-ERRa. Values are represented as a percentage of counts per minute, nor overexpression of NDRG2 levels (Fig. 4B). As ERRα upregulates
ribosome genes involved in protein translation [19,43] as well as
contractile- and mitochondrial-associated genes [14,20], we then in-
vestigated whether NDRG2 overexpression could inhibit any effects
that VP16-ERRα may have on protein synthesis. As shown in Fig. 4C,
VP16-ERRα expression increased protein synthesis rates by nearly
50% under basal conditions. Co-expression of exogenous NDRG2
attenuated the VP16-ERRα induction in protein synthesis by 16%
(P b 0.05; Fig. 4C).
4. Discussion
Here, we show for the ﬁrst time that Ndrg2 is induced following
an acute bout of endurance exercise and also by the transcriptionalC2C12myotubes. Protein synthesis (A) and degradation (B) rates following suppression of
hite bars) or retroviral infection ofNDRG2 (Ndrg2; black bars) compared to vector control
ne (dex) conditions for 24 h prior to harvesting. (C) Protein synthesis rates and immuno-
istical signiﬁcance in two-way ANOVAwith Bonferroni post-hoc analyses. Ndrg2 siRNA or
VP16-ERRa effect: ^P b 0.05 to basal siCON, vector or VP16 controls and #P b 0.05 to basal
= 4–6 samples per group. Two to four independent experiments were performed.
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ERRα. Additionally, through bioinformatics and in vitro biological assays
we show that NDRG2 contributes to protein synthesis rates, contractile
gene expression and MAPK signaling but does not appear to regulate
genes involved in mitochondrial biogenesis in differentiated muscle
cells indicating NDRG2 to have both separate and related roles to PGC-
1α/ERRα function.
The identiﬁcation of ERRE sequences in the mouse Ndrg2 5′ regula-
tory region and the subsequent in vitro experiments revealing PGC-
1α/ERRα regulation of Ndrg2 in this study indicate new roles for
NDRG2 linked to the PGC-1α/ERRα signaling program in skeletal mus-
cle (see Fig. 5). NDRG2 mRNA was increased in human skeletal muscle
following an acute endurance cycling exercise bout. We have shown
previously in the same human muscle samples that both PGC-1α and
ERRα expression are also elevated post exercise [16]. These paralleled
increases suggest the potential co-regulatory relationship between
NDRG2 and PGC-1α/ERRα activity following endurance exercise;
however this is yet to be experimentally validated (Fig. 5). WhileA
B
Fig. 5. Proposedmodel of PGC-1α/ERRα regulation of Ndrg2 in skeletal muscle. (A) A common
PGC-1α (TFs), is endurance exercise. Following activation, PGC-1α and ERRα are known to reg
the circle [14,19,20,22,66,67]. (B) Similarly to PGC-1α and ERRα, Ndrg2 is induced by enduran
though regulation of mitochondrial biogenesis is not apparent (crossed arrow). The role of ND
as well as the establishment of whether exercise induces Ndrg2 expression as a direct outcomethe gene and protein enrichment analyses from the Ndrg2 DNA micro-
array and iTRAQ proteomic screens also predict associations with
mitochondrial-linked metabolism, regulation of redox function, ribo-
somal activity and changes in myosin and contractile gene and protein
expression; processes linked to PGC-1α- and ERRα-regulated activities
in skeletal muscle in vitro and in vivo [14,20,26,36,42,44–46], not all
PGC-1α/ERRα downstream outcomes appear regulated by NDRG2
such as mitochondrial biogenesis. Furthermore, some of our ﬁndings
suggest that NDRG2 negatively regulate some of PGC-1α/ERRα effects.
For example, the genes in the OXPHOS and ribosome pathways, as
well as protein synthesis rates were increased following the suppres-
sion of Ndrg2. In contrast, enhanced NDRG2 levels reduced protein syn-
thesis both basally and in the presence of VP16-ERRα, which suggests
that NDRG2 may play a role in negatively modulating some ERRα
downstream effects. There may also be additional transcription factors
besides ERRα co-activated by PGC-1α to regulate Ndrg2 gene expres-
sion and this might be dependent on the cell type and stress condition.
For example, in liver cells the nuclear receptor the farnesoid X receptoractivator of PGC-1α and ERRα function, and of other transcriptional regulatory partners of
ulate a multitude of genes and downstream consequences in skeletal muscle as outlined in
ce exercise and also regulates downstream events common to PGC-1α/ERRα activity al-
RG2 in other related PGC-1α/ERRα-controlled activities still require further investigation
of PGC-1α/ERRα activation.
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pression via inverted repeat 1 (IR1)-type elements to help reduce liver
tumor cell growth and metastasis [47,48]. PGC-1α's involvement in
the co-activation of Ndrg2 by FXR was not reported in this study; how-
ever, PGC-1α enhances FXR regulation of hepatic bile acid and triglycer-
ide metabolism [49–51]. Combined, these results support a role for a
PGC-1α/orphan nuclear receptor signaling axis in the regulation of
Ndrg2 in metabolically active tissues.
The bioinformatics revealed consistent GO and UniProt terms, and
KEGG pathways at both the gene and protein levels, which gives greater
conﬁdence in the predicted roles for NDRG2 in skeletal muscle. In addi-
tion, some of the terms correlated well with emerging roles for NDRG2
in other cells types including vesicle-mediated and protein/ion trans-
port. A recent study has identiﬁed NDRG2 to interact with prenylated
Rab acceptor-1, a protein involved in vesicle trafﬁcking and protein
transport, to inhibit T-cell factor/beta-catenin signaling [52]. NDRG2
was found to interact with the beta1-subunit of Na(+)/K(+)-ATPase
to stabilize its expression and activity in Na(+) ion transport in epithe-
lial cells [7]. NDRG2may also regulate ion and vesicle transport in mus-
cle cells, however this has not been established. KEGGpathway analyses
revealed genes and proteins enriched in OXPHOS that overlapped with
the pathways associated with the metabolic-based neurodegenerative
diseases including Huntington's and Alzheimer's diseases. Some of the
pathogenicity of these diseases also manifests in skeletal muscle tissue
where reduced expression of PGC-1α and muscle function have been
documented such as in Huntington's transgenic mice [53,54]. Elevated
NDRG2 protein and phosphorylation levels have been detected post-
mortem in individuals with Alzheimer's and frontotemporal lobar de-
generation [55,56] suggesting a potential connection between NDRG2
and neurodegenerative diseases.
The changes in protein synthesis rates under both basal and insulin-
treated conditions followingNDRG2 suppression or overexpression cor-
responds with our previous observations that anabolic and catabolic
conditions reduce and enhance Ndrg2 mRNA levels, respectively [10]
(Fig. 6). The changes in protein synthesis may reﬂect remodeling as
indicated by altered myosin gene expression or with other ribosomal
or metabolically associate proteins not yet explored. In addition to
a role for NDRG2 in myogenesis in C2C12 cells [10], our microarray
and iTRAQ screens, and gene expression analyses in myotubes with
suppressed NDRG2, identiﬁed individual and groups of genes linked
with muscle development, regeneration and myopathies. For example,
Myh3 is involved in embryonic development and muscle regeneration
[57] and its mutation is linked to myopathy during fetal development
contributing to distal arthrogryposis [58]. Defective telethonin, which
was also downregulated in response to NDRG2 suppression, is linked
to congenital muscular dystrophy (reviewed in [59]). The implication
for highly reduced levels of Dysﬁp1/Ppp1r27 mRNA measured in this
study is unknown. This gene is not well characterized although it is pre-
dicted to interact and inhibit the phosphatase activity of protein phos-
phatase 1 complexes [60]. Whether it plays a role in the dystrophies
and myopathies associated with Dysferlin [61] is yet to be investigated.Fig. 6.Overview of factors and stress effects that induce or suppress NDRG2 levels in skel-
etal muscle and the known and predicted downstream effects as identiﬁed in this study
and previously [10]. OXPHOS, oxidative phosphorylation; ROS, reactive oxygen species.Changes in NDRG2 levels have been linked to MAPK signaling but
with no consistent outcome. For example, p38 MAPK and ERK1/2
phosphorylation levels either increase, decrease or do not change
in different cell types including breast cancer cells, and stimulated
monocytes and macrophages [62–64]. In C2C12 myotubes, NDRG2
suppression or overexpression does not appear to regulate the ex-
pression of p38 MAPK and/or ERK1/2 under basal conditions. In con-
trast, the total and phosphorylated level of p90 RSK1, a downstream
target of ERK1/2, was reduced signiﬁcantly with NDRG2 knock-
down. To our knowledge, the regulation of p90 RSK by NDRG2 has
not been reported before and the signiﬁcance of its down regulation
is currently unknown. The phosphorylation of p90 RSK may increase
following activation of protein synthesis [65], but whether elevated
p90 RSK1 activity is required for increased protein synthesis rates
in C2C12 myotubes under the conditions used in this study is not
known.
In conclusion, this study demonstrates for the ﬁrst time the induc-
tion of Ndrg2 gene expression by the PGC-1α/ERRα transcriptional
complex in C2C12myotubes. We also established that myotube protein
synthesis and faster twitch myosin heavy chain isoforms are elevated
when NDRG2 levels are suppressed. Elevating NDRG2 attenuates the
ERRα-induction ofmyotube protein synthesis, but notmRNA expression
of genes involved in mitochondrial biogenesis suggesting that NDRG2
may play a selective role in regulating the effects PGC-1α/ERRα. The ge-
nomic and proteomic screens performed predict further novel biological
processes inﬂuenced by NDRG2 in differentiated muscle cells, many of
which await future investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.08.011.
Acknowledgements
This work was supported by the Centre for Physical Activity and
Nutrition Research, Deakin University. The authors thank Dr. David
Segal for critical reading of the manuscript. YC and AK were supported
by the American Heart Association (AHA # 12POST8610009) and
NIDDK (R01DK095686 to AK).
References
[1] V. Melotte, X. Qu, M. Ongenaert, W. van Criekinge, A.P. de Bruine, H.S. Baldwin, M.
van Engeland, The N-myc downstream regulated gene (NDRG) family: diverse func-
tions, multiple applications, FASEB J. 24 (2010) 4153–4166.
[2] S. Boulkroun, M. Fay, M.C. Zennaro, B. Escoubet, F. Jaisser, M. Blot-Chabaud, N.
Farman, N. Courtois-Coutry, Characterization of rat NDRG2 (N-Myc downstream
regulated gene 2), a novel early mineralocorticoid-speciﬁc induced gene, J. Biol.
Chem. 277 (2002) 31506–31515.
[3] X. Qu, Y. Zhai, H. Wei, C. Zhang, G. Xing, Y. Yu, F. He, Characterization and expression
of three novel differentiation-related genes belong to the human NDRG gene family,
Mol. Cell. Biochem. 229 (2002) 35–44.
[4] J.T. Murray, D.G. Campbell, N. Morrice, G.C. Auld, N. Shpiro, R. Marquez, M. Peggie, J.
Bain, G.B. Bloomberg, F. Grahammer, F. Lang, P.Wulff, D. Kuhl, P. Cohen, Exploitation
of KESTREL to identify NDRG family members as physiological substrates for SGK1
and GSK3, Biochem. J. 384 (2004) 477–488.
[5] Y. Deng, L. Yao, L. Chau, S.S. Ng, Y. Peng, X. Liu, W.S. Au, J. Wang, F. Li, S. Ji, H. Han,
X. Nie, Q. Li, H.F. Kung, S.Y. Leung, M.C. Lin, N-Myc downstream-regulated gene 2
(NDRG2) inhibits glioblastoma cell proliferation, Int. J. Cancer 106 (2003)
342–347.
[6] X.L. Hu, X.P. Liu, S.X. Lin, Y.C. Deng, N. Liu, X. Li, L.B. Yao, NDRG2 expression and
mutation in human liver and pancreatic cancers, World J. Gastroenterol. 10 (2004)
3518–3521.
[7] Y. Li, J. Yang, S. Li, J. Zhang, J. Zheng, W. Hou, H. Zhao, Y. Guo, X. Liu, K. Dou, Z. Situ, L.
Yao, N-myc downstream-regulated gene 2, a novel estrogen-targeted gene, is involved
in the regulation of Na+/K + -ATPase, J. Biol. Chem. 286 (2011) 32289–32299.
[8] J. Yang, J. Zheng, L. Wu, M. Shi, H. Zhang, X.Wang, N. Xia, D.Wang, X. Liu, L. Yao, Y. Li,
K. Dou, NDRG2 ameliorates hepatic ﬁbrosis by inhibiting the TGF-beta1/Smad path-
way and altering the MMP2/TIMP2 ratio in rats, PLoS One 6 (2011) e27710.
[9] L. Shen, X. Liu, W. Hou, G. Yang, Y. Wu, R. Zhang, X. Li, H. Che, Z. Lu, Y. Zhang, L. Yao,
NDRG2 is highly expressed in pancreatic beta cells and involved in protection
against lipotoxicity, Cell. Mol. Life Sci. 67 (2010) 1371–1381.
[10] V.C. Foletta, M.J. Prior, N. Stupka, K. Carey, D.H. Segal, S. Jones, C. Swinton, S.
Martin, D. Cameron-Smith, K.R. Walder, NDRG2, a novel regulator of myoblast
proliferation, is regulated by anabolic and catabolic factors, J. Physiol. 587 (2009)
1619–1634.
3122 V.C. Foletta et al. / Biochimica et Biophysica Acta 1833 (2013) 3112–3123[11] K. Hojlund, B.P. Bowen, H. Hwang, C.R. Flynn, L. Madireddy, T. Geetha, P. Langlais, C.
Meyer, L.J. Mandarino, Z. Yi, In vivo phosphoproteome of human skeletal muscle re-
vealed by phosphopeptide enrichment and HPLC-ESI-MS/MS, J. Proteome Res. 8
(2009) 4954–4965.
[12] J.G. Burchﬁeld, A.J. Lennard, S. Narasimhan,W.E. Hughes, V.C. Wasinger, G.L. Corthals,
T. Okuda, H. Kondoh, T.J. Biden, C. Schmitz-Peiffer, Akt mediates insulin-stimulated
phosphorylation of Ndrg2: evidence for cross-talk with protein kinase C theta,
J. Biol. Chem. 279 (2004) 18623–18632.
[13] J.H. Chang, K.H. Lin, C.H. Shih, Y.J. Chang, H.C. Chi, S.L. Chen, Myogenic basic
helix-loop-helix proteins regulate the expression of peroxisomal proliferator acti-
vated receptor-gamma coactivator-1alpha, Endocrinology 147 (2006) 3093–3106.
[14] J. Murray, J.M. Huss, Estrogen-related receptor alpha regulates skeletal myocyte dif-
ferentiation via modulation of the ERK MAP kinase pathway, Am. J. Physiol. Cell
Physiol. 301 (2011) C630–C645.
[15] R. Cartoni, B. Leger, M.B. Hock, M. Praz, A. Crettenand, S. Pich, J.L. Ziltener, F. Luthi, O.
Deriaz, A. Zorzano, C. Gobelet, A. Kralli, A.P. Russell, Mitofusins 1/2 and ERRalpha ex-
pression are increased in human skeletal muscle after physical exercise, J. Physiol.
567 (2005) 349–358.
[16] M.A. Wallace, M.B. Hock, B.C. Hazen, A. Kralli, R.J. Snow, A.P. Russell, Striated muscle
activator of Rho signalling (STARS) is a PGC-1alpha/oestrogen-related receptor-alpha
target gene and is upregulated in human skeletal muscle after endurance exercise,
J. Physiol. 589 (2011) 2027–2039.
[17] T. Hong, J. Ning, X. Yang, H.Y. Liu, J. Han, Z. Liu, W. Cao, Fine-tuned regulation of the
PGC-1alpha gene transcription by different intracellular signaling pathways, Am. J.
Physiol. Endocrinol. Metab. 300 (2011) E500–E507.
[18] W. Xu, T. Guo, Y. Zhang, X. Jiang, K. Zen, B. Yu, C.Y. Zhang, The inhibitory effect of
dexamethasone on platelet-derived growth factor-induced vascular smooth muscle
cell migration through up-regulating PGC-1alpha expression, Exp. Cell Res. 317
(2011) 1083–1092.
[19] R.C. Scarpulla, Transcriptional paradigms in mammalian mitochondrial biogenesis
and function, Physiol. Rev. 88 (2008) 611–638.
[20] J.M. Huss, I.P. Torra, B. Staels, V. Giguere, D.P. Kelly, Estrogen-related receptor alpha
directs peroxisome proliferator-activated receptor alpha signaling in the transcrip-
tional control of energy metabolism in cardiac and skeletal muscle, Mol. Cell. Biol.
24 (2004) 9079–9091.
[21] V.K. Mootha, C. Handschin, D. Arlow, X. Xie, J. St Pierre, S. Sihag, W. Yang, D.
Altshuler, P. Puigserver, N. Patterson, P.J. Willy, I.G. Schulman, R.A. Heyman, E.S.
Lander, B.M. Spiegelman, Erralpha and Gabpa/b specify PGC-1alpha-dependent
oxidative phosphorylation gene expression that is altered in diabetic muscle, Proc.
Natl. Acad. Sci. U. S. A. 101 (2004) 6570–6575.
[22] A.R. Wende, J.M. Huss, P.J. Schaeffer, V. Giguere, D.P. Kelly, PGC-1alpha coactivates
PDK4 gene expression via the orphan nuclear receptor ERRalpha: a mechanism
for transcriptional control of muscle glucose metabolism, Mol. Cell. Biol. 25 (2005)
10684–10694.
[23] S.N. Schreiber, R. Emter, M.B. Hock, D. Knutti, J. Cardenas, M. Podvinec, E.J. Oakeley,
A. Kralli, The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma
coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis, Proc. Natl. Acad.
Sci. U. S. A. 101 (2004) 6472–6477.
[24] A.P. Russell, S. Wada, L. Vergani, M.B. Hock, S. Lamon, B. Leger, T. Ushida, R. Cartoni,
G.D. Wadley, P. Hespel, A. Kralli, G. Soraru, C. Angelini, T. Akimoto, Disruption of
skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral
sclerosis, Neurobiol. Dis. 49C (2012) 107–117.
[25] J. Lin, H. Wu, P.T. Tarr, C.Y. Zhang, Z. Wu, O. Boss, L.F. Michael, P. Puigserver, E.
Isotani, E.N. Olson, B.B. Lowell, R. Bassel-Duby, B.M. Spiegelman, Transcriptional
co-activator PGC-1 alpha drives the formation of slow-twitch muscle ﬁbres, Nature
418 (2002) 797–801.
[26] K.A. Rasbach, R.K. Gupta, J.L. Ruas, J. Wu, E. Naseri, J.L. Estall, B.M. Spiegelman,
PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal muscle ﬁber
types, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 21866–21871.
[27] R. Sladek, J.A. Bader, V. Giguere, The orphan nuclear receptor estrogen-related re-
ceptor alpha is a transcriptional regulator of the human medium-chain acyl coen-
zyme A dehydrogenase gene, Mol. Cell. Biol. 17 (1997) 5400–5409.
[28] L. Chen, S.N. Willis, A. Wei, B.J. Smith, J.I. Fletcher, M.G. Hinds, P.M. Colman, C.L. Day,
J.M. Adams, D.C. Huang, Differential targeting of prosurvival Bcl-2 proteins by their
BH3-only ligands allows complementary apoptotic function, Mol. Cell 17 (2005)
393–403.
[29] S. Morita, T. Kojima, T. Kitamura, Plat-E: an efﬁcient and stable system for transient
packaging of retroviruses, Gene Ther. 7 (2000) 1063–1066.
[30] R. Akamine, T. Yamamoto, M. Watanabe, N. Yamazaki, M. Kataoka, M. Ishikawa, T.
Ooie, Y. Baba, Y. Shinohara, Usefulness of the 5' region of the cDNA encoding acidic
ribosomal phosphoprotein P0 conserved among rats, mice, and humans as a stan-
dard probe for gene expression analysis in different tissues and animal species,
J. Biochem. Biophys. Methods 70 (2007) 481–486.
[31] P. Du, W.A. Kibbe, S.M. Lin, Lumi: a pipeline for processing Illumina microarray, Bio-
informatics 24 (2008) 1547–1548.
[32] S.M. Lin, P. Du, W. Huber, W.A. Kibbe, Model-based variance-stabilizing transforma-
tion for Illumina microarray data, Nucleic Acids Res. 36 (2008) e11.
[33] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources, Nat. Protoc. 4 (2009) 44–57.
[34] W. Huang da, B.T. Sherman, R.A. Lempicki, Bioinformatics enrichment tools: paths
toward the comprehensive functional analysis of large gene lists, Nucleic Acids
Res. 37 (2009) 1–13.
[35] T. Casey, P.S. Solomon, S. Bringans, K.C. Tan, R.P. Oliver, R. Lipscombe, Quantita-
tive proteomic analysis of G-protein signalling in Stagonospora nodorum using
isobaric tags for relative and absolute quantiﬁcation, Proteomics 10 (2010)
38–47.[36] J.J. Brault, J.G. Jespersen, A.L. Goldberg, Peroxisome proliferator-activated receptor
gamma coactivator 1alpha or 1beta overexpression inhibitsmuscle protein degrada-
tion, induction of ubiquitin ligases, and disuse atrophy, J. Biol. Chem. 285 (2010)
19460–19471.
[37] C.R. Dufour, B.J. Wilson, J.M. Huss, D.P. Kelly, W.A. Alaynick, M. Downes, R.M.
Evans, M. Blanchette, V. Giguere, Genome-wide orchestration of cardiac func-
tions by the orphan nuclear receptors ERRalpha and gamma, Cell Metab. 5 (2007)
345–356.
[38] S.N. Schreiber, D. Knutti, K. Brogli, T. Uhlmann, A. Kralli, The transcriptional
coactivator PGC-1 regulates the expression and activity of the orphan nuclear
receptor estrogen-related receptor alpha (ERRalpha), J. Biol. Chem. 278 (2003)
9013–9018.
[39] P.L. Ross, Y.N. Huang, J.N.Marchese, B.Williamson, K. Parker, S. Hattan, N. Khainovski,
S. Pillai, S. Dey, S. Daniels, S. Purkayastha, P. Juhasz, S. Martin, M. Bartlet-Jones, F. He,
A. Jacobson, D.J. Pappin,Multiplexedprotein quantitation in Saccharomyces cerevisiae
using amine-reactive isobaric tagging reagents, Mol. Cell Proteomics 3 (2004)
1154–1169.
[40] A. Gallanti, A. Prelle, M. Moggio, P. Ciscato, N. Checcarelli, M. Sciacco, A. Comini, G.
Scarlato, Desmin and vimentin as markers of regeneration in muscle diseases,
Acta Neuropathol. 85 (1992) 88–92.
[41] A. Bornemann, H. Schmalbruch, Desmin and vimentin in regenerating muscles,
Muscle Nerve 15 (1992) 14–20.
[42] O.H. Mortensen, L. Frandsen, P. Schjerling, E. Nishimura, N. Grunnet, PGC-1alpha and
PGC-1beta have both similar and distinct effects on myoﬁber switching toward an
oxidative phenotype, Am. J. Physiol. Endocrinol. Metab. 291 (2006) E807–E816.
[43] V. Giguere, Transcriptional control of energy homeostasis by the estrogen-related
receptors, Endocr. Rev. 29 (2008) 677–696.
[44] Z. Arany, PGC-1 coactivators and skeletal muscle adaptations in health and disease,
Curr. Opin. Genet. Dev. 18 (2008) 426–434.
[45] C. Handschin, S. Chin, P. Li, F. Liu, E. Maratos-Flier, N.K. Lebrasseur, Z. Yan, B.M.
Spiegelman, Skeletal muscle ﬁber-type switching, exercise intolerance, and myopa-
thy in PGC-1alpha muscle-speciﬁc knock-out animals, J. Biol. Chem. 282 (2007)
30014–30021.
[46] J. St-Pierre, S. Drori, M. Uldry, J.M. Silvaggi, J. Rhee, S. Jager, C. Handschin, K. Zheng, J.
Lin,W. Yang, D.K. Simon, R. Bachoo, B.M. Spiegelman, Suppression of reactive oxygen
species and neurodegeneration by the PGC-1 transcriptional coactivators, Cell 127
(2006) 397–408.
[47] U. Deuschle, J. Schuler, A. Schulz, T. Schluter, O. Kinzel, U. Abel, C. Kremoser, FXR
controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth
andmetastasis in an orthotopicmouse xenograft model, PLoS One 7 (2012) e43044.
[48] C. Langhi, E. Pedraz-Cuesta, Y. Donate, P.F. Marrero, D. Haro, J.C. Rodriguez, Regula-
tion of N-Myc downstream regulated gene 2 by bile acids, Biochem. Biophys. Res.
Commun. 434 (2013) 102–109.
[49] E. Kanaya, T. Shiraki, H. Jingami, The nuclear bile acid receptor FXR is activated by
PGC-1alpha in a ligand-dependent manner, Biochem. J. 382 (2004) 913–921.
[50] Y. Zhang, L.W. Castellani, C.J. Sinal, F.J. Gonzalez, P.A. Edwards, Peroxisome
proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates
triglyceride metabolism by activation of the nuclear receptor FXR, Genes Dev. 18
(2004) 157–169.
[51] R.S. Savkur, J.S. Thomas, K.S. Bramlett, Y. Gao, L.F.Michael, T.P. Burris, Ligand-dependent
coactivation of the human bile acid receptor FXR by the peroxisome proliferator-
activated receptor gamma coactivator-1alpha, J. Pharmacol. Exp. Ther. 312 (2005)
170–178.
[52] J.T. Kim, J.W. Kim, Y.H. Kang, K.D. Kim, S.J. Lee, S.C. Choi, K.S. Kim, S.K. Chae, J.W. Kim,
J.S. Lim, H.G. Lee, NDRG2 and PRA1 interact and synergistically inhibit T-cell
factor/beta-catenin signaling, FEBS Lett. 586 (2012) 3962–3968.
[53] R.K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A.
Starkov, M. Kiaei, M. Cannella, J. Sassone, A. Ciammola, F. Squitieri, M.F. Beal, Im-
paired PGC-1alpha function in muscle in Huntington's disease, Hum. Mol. Genet.
18 (2009) 3048–3065.
[54] K. Rona-Voros, P.Weydt, The role of PGC-1alpha in the pathogenesis of neurodegen-
erative disorders, Curr. Drug Targets 11 (2010) 1262–1269.
[55] C. Mitchelmore, S. Buchmann-Moller, L. Rask, M.J. West, J.C. Troncoso, N.A. Jensen,
NDRG2: a novel Alzheimer's disease associated protein, Neurobiol. Dis. 16 (2004)
48–58.
[56] J.H. Herskowitz, N.T. Seyfried, D.M. Duong, Q. Xia, H.D. Rees, M. Gearing, J. Peng, J.J.
Lah, A.I. Levey, Phosphoproteomic analysis reveals site-speciﬁc changes in GFAP
and NDRG2 phosphorylation in frontotemporal lobar degeneration, J. Proteome
Res. 9 (2010) 6368–6379.
[57] I. Karsch-Mizrachi, M. Travis, H. Blau, L.A. Leinwand, Expression and DNA sequence
analysis of a human embryonic skeletal muscle myosin heavy chain gene, Nucleic
Acids Res. 17 (1989) 6167–6179.
[58] H. Tajsharghi, E. Kimber, A.K. Kroksmark, R. Jerre, M. Tulinius, A. Oldfors, Embry-
onic myosin heavy-chain mutations cause distal arthrogryposis and develop-
mental myosin myopathy that persists postnatally, Arch. Neurol. 65 (2008)
1083–1090.
[59] A. Ferreiro, M. Mezmezian, M. Olive, D. Herlicoviez, M. Fardeau, P. Richard, N.B.
Romero, Telethonin-deﬁciency initially presenting as a congenital muscular dystro-
phy, Neuromuscul. Disord. 21 (2011) 433–438.
[60] A. Hendrickx, M. Beullens, H. Ceulemans, T. Den Abt, A. Van Eynde, E. Nicolaescu, B.
Lesage, M. Bollen, Docking motif-guided mapping of the interactome of protein
phosphatase-1, Chem. Biol. 16 (2009) 365–371.
[61] D. Bansal, K.P. Campbell, Dysferlin and the plasma membrane repair in muscular
dystrophy, Trends Cell Biol. 14 (2004) 206–213.
[62] S.C. Choi, K.D. Kim, J.T. Kim, S.S. Oh, S.Y. Yoon, E.Y. Song, H.G. Lee, Y.K. Choe, I. Choi,
J.S. Lim, J.W. Kim, NDRG2 is one of novel intrinsic factors for regulation of IL-10
3123V.C. Foletta et al. / Biochimica et Biophysica Acta 1833 (2013) 3112–3123production in human myeloid cell, Biochem. Biophys. Res. Commun. 396 (2010)
684–690.
[63] S. Liu, P. Yang, H. Kang, L. Lu, Y. Zhang, J. Pan, Y.C. Rui, NDRG2 induced by oxidized
LDL inmacrophages antagonizes growth factor productions via selectively inhibiting
ERK activation, Biochim. Biophys. Acta 1801 (2010) 106–113.
[64] Y. Park, S.K. Shon, A. Kim, K.I. Kim, Y. Yang, D.H. Cho, M.S. Lee, J.S. Lim, SOCS1 in-
duced by NDRG2 expression negatively regulates STAT3 activation in breast cancer
cells, Biochem. Biophys. Res. Commun. 363 (2007) 361–367.
[65] L.Q. Hong-Brown, C.R. Brown, D.S. Huber, C.H. Lang, Alcohol and indinavir
adversely affect protein synthesis and phosphorylation of MAPK and mTORsignaling pathways in C2C12 myocytes, Alcohol. Clin. Exp. Res. 30 (2006)
1297–1307.
[66] J. Chinsomboon, J. Ruas, R.K. Gupta, R. Thom, J. Shoag, G.C. Rowe, N. Sawada, S.
Raghuram, Z. Arany, The transcriptional coactivator PGC-1alpha mediates exercise-
induced angiogenesis in skeletal muscle, Proc. Natl. Acad. Sci. U. S. A. 106 (2009)
21401–21406.
[67] S. Summermatter, G. Santos, J. Perez-Schindler, C. Handschin, Skeletal muscle
PGC-1alpha controls whole-body lactate homeostasis through estrogen-related re-
ceptor alpha-dependent activation of LDH B and repression of LDH A, Proc. Natl.
Acad. Sci. U. S. A. 110 (2013) 8738–8743.
